Land: Schweiz
Sprache: Deutsch
Quelle: Swissmedic (Swiss Agency for Therapeutic Products)
levodopum, benserazidum
Roche Pharma (Schweiz) AG
N04BA02
levodopum, benserazidum
Kapseln
levodopum 100.0 mg, benserazidum 25.0 mg ut benserazidi hydrochloridum, hypromellosum, oleum vegetabile hydrogenatum, calcii hydrogenophosphas, mannitolum, povidonum K 30, talcum, magnesii stearas, Kapselhülle: E 132, E 171, gelatina, E 172 (flavum), Drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, E 172 (rubrum), pro capsula.
B
Synthetika
Morbus Parkinson, Restless-Legs-Syndrom
zugelassen
1987-06-18